Nuvilex Inc. (NASDAQ:PMCB) Stock Short Interest Report for October

Nuvilex Inc. (NASDAQ:PMCB) saw a large drop in short interest in the month of October. As of October 15th, there was short interest totaling 70,104 shares, a drop of 47.6% from the September 30th total of 133,885 shares. Based on an average daily trading volume, of 99,423 shares, the short-interest ratio is presently 0.7 days. Approximately 0.7% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut Nuvilex from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, September 2nd. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat, Nuvilex presently has a consensus rating of “Sell”.

Nuvilex Trading Down 9.0%

NASDAQ:PMCB traded down $0.03 during mid-day trading on Friday, hitting $0.30. The stock had a trading volume of 121,688 shares, compared to its average volume of 69,269. Nuvilex has a twelve month low of $0.30 and a twelve month high of $1.51. The stock has a 50-day simple moving average of $0.42 and a two-hundred day simple moving average of $0.65. The company has a market capitalization of $3.24 million, a PE ratio of -0.13 and a beta of 0.68.

Nuvilex (NASDAQ:PMCB) last posted its quarterly earnings results on Monday, September 14th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.48).

About Nuvilex

Nuvilex, Inc was a biotechnology company that later changed its name to PharmaCyte Biotech, Inc and continued to trade under the ticker symbol PMCB. The company focused on developing cellular therapies intended to treat serious diseases, particularly cancer and diabetes.

Its primary technology involved encapsulating genetically engineered human cells in proprietary cellulose-based capsules. These cells were designed to produce therapeutic substances inside the body while limiting exposure to healthy tissue.